Recordati Industria Chimica e Farmaceutica (RCDTF) Stock Price, News & Analysis

Company Overview

Recordati Industria Chimica e Farmaceutica S.p.A., together with its subsidiaries, engages in the research, development, manufacture, and marketing of pharmaceuticals worldwide. The company operates through Specialty and Primary Care and Rare Diseases segments. Its product pipeline includes REC 0559 which is in Phase II for the treatment of Neurotrophic Keratitis; REC 0545 for acute decompensation in maple syrup urine diseases; ISTURISA for endogenous Cushing's syndrome; and CYSTADROPS, an corneal cystine deposits in patients with cystinosis. The company also develops CARBAGLU for hyperammonemia due to NAGS deficiency; QARZIBA, an apeiron for the treatment of high-risk neuroblastoma patients with a partial response at the chemotherapeutical through myeloablative therapy and stem cell transplantation, and relapsed or refractory neuroblastoma. In addition, it offers SYLVANT for the treatment of idiopathic multicentric Castleman diseases; REAGILA for Schizophrenia; and ELIGARD for hormone-dependent prostate cancer, as well as CAPHOSOL, a medical device for treatment of oral mucositis due to chemo and radiation therapy. The company was founded in 1926 and is headquartered in Milan, Italy. Recordati Industria Chimica e Farmaceutica S.p.A. operates as a subsidiary of Rossini S.à R.L.

Key Stats

• Today's Range: $52.25 to $52.25
• 50-Day Range: $51.60 to $52.25
• 52-Week Range: $52.25 to $52.25
• Volume: N/A
• Average Volume: 0 shs
• Market Capitalization: N/A
• P/E Ratio: 18.80
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

RCDTF Stock Analysis - Frequently Asked Questions

How have RCDTF shares performed this year?

Recordati Industria Chimica e Farmaceutica's stock was trading at $46.00 on January 1st, 2024. Since then, RCDTF stock has increased by 13.6% and is now trading at $52.25.
View the best growth stocks for 2024 here.

How were Recordati Industria Chimica e Farmaceutica's earnings last quarter?

Recordati Industria Chimica e Farmaceutica S.p.A. (OTCMKTS:RCDTF) issued its quarterly earnings data on Tuesday, July, 30th. The company reported $0.70 EPS for the quarter. The business earned $622 million during the quarter. Recordati Industria Chimica e Farmaceutica had a net margin of 17.41% and a trailing twelve-month return on equity of 30.78%.

How do I buy shares of Recordati Industria Chimica e Farmaceutica?

Shares of RCDTF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Company Calendar

• Last Earnings: 7/30/2024
• Today: 9/29/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Private households
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:RCDTF
• Previous Symbol: NASDAQ:RCDTF
• CUSIP: N/A
• CIK: N/A
• Web: www.recordati.com
• Phone: 390-248-7871
• Fax: 39-02-4007-3747
• Employees: 4,455
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: 18.80
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $421.25 million
• Net Margins: 17.41%
• Pretax Margin: 23.58%
• Return on Equity: 30.78%
• Return on Assets: 12.65%

Debt

• Debt-to-Equity Ratio: 0.73
• Current Ratio: 1.36
• Quick Ratio: 0.95

Sales & Book Value

• Annual Sales: $2.25 billion
• Price / Sales: N/A
• Cash Flow: $3.06 per share
• Price / Cash Flow: 17.08
• Book Value: $7.90 per share
• Price / Book: 6.61

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: 0.33